JP2024515301A5 - - Google Patents

Info

Publication number
JP2024515301A5
JP2024515301A5 JP2023563833A JP2023563833A JP2024515301A5 JP 2024515301 A5 JP2024515301 A5 JP 2024515301A5 JP 2023563833 A JP2023563833 A JP 2023563833A JP 2023563833 A JP2023563833 A JP 2023563833A JP 2024515301 A5 JP2024515301 A5 JP 2024515301A5
Authority
JP
Japan
Prior art keywords
polypeptide
domain
hinge
terminus
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023563833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515301A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/025340 external-priority patent/WO2022225921A1/en
Publication of JP2024515301A publication Critical patent/JP2024515301A/ja
Publication of JP2024515301A5 publication Critical patent/JP2024515301A5/ja
Pending legal-status Critical Current

Links

JP2023563833A 2021-04-20 2022-04-19 多重特異性及び一価のigg分子の会合における鎖対形成の静電ステアリングにおけるバランスのとれた電荷分布 Pending JP2024515301A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163177325P 2021-04-20 2021-04-20
US63/177,325 2021-04-20
PCT/US2022/025340 WO2022225921A1 (en) 2021-04-20 2022-04-19 Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly

Publications (2)

Publication Number Publication Date
JP2024515301A JP2024515301A (ja) 2024-04-08
JP2024515301A5 true JP2024515301A5 (cg-RX-API-DMAC7.html) 2025-04-25

Family

ID=81580206

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023563833A Pending JP2024515301A (ja) 2021-04-20 2022-04-19 多重特異性及び一価のigg分子の会合における鎖対形成の静電ステアリングにおけるバランスのとれた電荷分布

Country Status (8)

Country Link
US (1) US20240182600A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326761A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024515301A (cg-RX-API-DMAC7.html)
CN (1) CN117651714A (cg-RX-API-DMAC7.html)
AU (1) AU2022263406A1 (cg-RX-API-DMAC7.html)
CA (1) CA3216559A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012324A (cg-RX-API-DMAC7.html)
WO (1) WO2022225921A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR134814A1 (es) * 2023-12-21 2026-04-15 Amgen Inc Mutaciones estabilizadoras de homodímeros para la producción de heterodímeros bicelulares

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JPH06508035A (ja) 1991-06-14 1994-09-14 ディーエヌエックス コーポレーション トランスジェニックブタにおけるヒトヘモグロビンの生産
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
NZ581468A (en) 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
US9527927B2 (en) * 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
IL321475A (en) * 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
CA3025162A1 (en) * 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
WO2020264384A1 (en) * 2019-06-28 2020-12-30 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins

Similar Documents

Publication Publication Date Title
JP7068251B2 (ja) T細胞再標的化ヘテロ二量体免疫グロブリン(hetero-dimeric immunoglobulin)の製造
AU2020359928B2 (en) CD3-targeting antibody, bispecific antibody and use thereof
JP2022545647A5 (cg-RX-API-DMAC7.html)
JP6157046B2 (ja) 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
JP7503642B2 (ja) 微小ガイダンス及びナビゲーションコントロール(miniGNC)抗体様タンパク質、その製造方法及び使用方法
JP2020508655A5 (cg-RX-API-DMAC7.html)
JP2023538945A5 (cg-RX-API-DMAC7.html)
US20220340677A1 (en) Split intein and preparation method for recombinant polypeptide using the same
WO2013064701A2 (en) Bispecific antibodies and methods for isolating same
KR20200013233A (ko) 신규 항 cd3 항체
JP2022504826A5 (cg-RX-API-DMAC7.html)
JP2023139025A (ja) 二重特異性抗原結合コンストラクト
WO2022166728A1 (zh) 双特异性抗体
JP2023508366A (ja) 二重特異性fcyriii×cd30抗体構築体の製造方法
JP2024507693A5 (cg-RX-API-DMAC7.html)
EP3641815A1 (en) A TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT FOR CANCER THERAPY
CA3229160A1 (en) Bispecific tetravalent antibody targeting egfr and her3
TW202222824A (zh) Egfr結合複合物及其製備和使用方法
JP2024516098A5 (cg-RX-API-DMAC7.html)
JP2026513915A (ja) ヒンジが修飾された二重特異性抗体
JP2026508244A (ja) 抗Nectin-4抗体及びそれを含む多重特異性抗体
RU2010122044A (ru) УЛУЧШЕННЫЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Nogo-А И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
US20180371089A1 (en) Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecific antibody and uses thereof in caner therapy
US20240262929A1 (en) Anti-muc16 antibodies
US20240376222A1 (en) Tfr antigen binding proteins and uses thereof